ClinicalTrials.gg
CompletedNCT03269435Updated Sep 22, 2021Results posted

Greater Occipital Nerve Block Versus Metoclopramide

A Phase 4 interventional study of Greater occipital nerve block with bupivacaine and Metoclopramide in Migraine, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-22.

Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Migraine Disorders by Montefiore Medical Center — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Montefiore Medical Center.

Enrollment
10th of 14
99 · median 207
Started
2017
with 1 other
Phase 4
9 of 15
none open now
Registered
13th of 15
by date

Among the 15 studies in Migraine Disorders by Montefiore Medical Center, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 13th registered.

Migraine Disorders

1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 15 studies in Migraine Disorders by Montefiore Medical Center is open now. The open studies under Migraine Disorders, anywhere →

Where they have run

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Migraine Disorders by Montefiore Medical Center as a file.
02

Study summary

We are comparing a type of nerve block called greater occipital nerve block versus standard therapy among patients who present to an emergency department for acute migraine. This is a randomized, double-blind, double dummy study. The greater occipital nerve block will be performed bilaterally with bupivacaine 0.5%. Standard therapy is metoclopramide 10mg IV.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients are adults who present with an acute moderate or severe headache meeting migraine headache criteria, as defined by the International Classification of Headache Disorders-3β (1.1, migraine without aura). Patients who meet criteria for Probable Migraine without Aura (1.5.1) will also be included, provided they have had at least one similar attack previously.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if cannot be obtained, if there is concern for a secondary cause of headache, if the maximum documented temperature is greater than 100.3 degrees, for a new objective neurologic abnormality, skull defect, suspected infection overlying injection site, known bleeding disorder, ongoing use of anti- agents including P2Y12 platelet inhibitors (clopidogrel, prasugrel, ticagrelor), heparins, warfarin, or 10a inhibitors (rivaroxaban, apixaban, edoxaban, fondaparinux), prior treatment with a greater occipital nerve block, allergy to the medications, pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Greater Occipital Nerve Block

    Bilateral greater occipital nerve block with bupivacaine 0.5% + Normal saline IV

    Procedure: Greater occipital nerve block with bupivacaine

  • Active comparator
    Metoclopramide

    Metoclopramide 10mg IV + Bilateral greater occipital nerve block with normal saline

    Drug: Metoclopramide

Interventions

  • ProcedureGreater occipital nerve block with bupivacaine

    This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally

  • Metoclopramide 10mg IV will be administered over 15 minutes

06

What researchers measure

Primary outcomes

  1. 0-10 Pain Score

    Pain score assessed at baseline and one hour. 0= no pain, 10 = worst imaginable. This outcome is the change in pain between baseline and one hour

    Time frame: one hour

Secondary outcomes

  1. Sustained Headache Relief

    Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication

    Time frame: 48 hours

  2. Sustained Headache Freedom

    Headache = none, achieved in emergency department and maintained for 48 hours

    Time frame: 48 hours

07

Results

Posted Sep 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneGreater Occipital Nerve BlockMetoclopramide
Started5148
Completed5148
Not completed00

Outcome measures

Primary0-10 Pain Score

Pain score assessed at baseline and one hour. 0= no pain, 10 = worst imaginable. This outcome is the change in pain between baseline and one hour

Time frame:
one hour
Reported as:
Mean · units on a scale
0-10 Pain Score
units on a scaleGreater Occipital Nerve BlockMetoclopramide
0-10 Pain Score5.0 (4.1 to 5.8)6.1 (5.2 to 6.9)
SecondarySustained Headache Relief

Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication

Time frame:
48 hours
Reported as:
Count of participants · Participants
Sustained Headache Relief
ParticipantsGreater Occipital Nerve BlockMetoclopramide
Sustained Headache Relief1118
SecondarySustained Headache Freedom

Headache = none, achieved in emergency department and maintained for 48 hours

Time frame:
48 hours
Reported as:
Count of participants · Participants
Sustained Headache Freedom
ParticipantsGreater Occipital Nerve BlockMetoclopramide
Sustained Headache Freedom37

Adverse events

Collected over 48 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Greater Occipital Nerve Block0/51 (0%)0/51 (0%)16/51 (31.4%)
Metoclopramide0/48 (0%)0/48 (0%)18/48 (37.5%)
Most frequent other events
Most frequent other events
EventGreater Occipital Nerve BlockMetoclopramide
VariousInvestigations1/519/48
DizzinessNervous system disorders4/513/48
head numbnessInjury, poisoning and procedural complications4/510/48
drowsinessNervous system disorders0/513/48
headacheNervous system disorders3/512/48
Injection site reactionInjury, poisoning and procedural complications2/511/48
Gastrointestinal symptomsGastrointestinal disorders2/510/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Greater Occipital Nerve BlockMetoclopramideTotal
Mean39 ± 1138 ± 1139 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Greater Occipital Nerve BlockMetoclopramideTotal
Female443478
Male71421
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Greater Occipital Nerve BlockMetoclopramideTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Greater Occipital Nerve BlockMetoclopramideTotal
United States514899
Baseline pain intensity
Baseline pain intensity(Participants)Greater Occipital Nerve BlockMetoclopramideTotal
Severe pain383573
Moderate pain131326
08

Study locations

1 site
  • Montefiore Medical Center
    Bronx, New York 10467, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2020, 28 months.

Results were first posted in Sep 2021, 1 year 6 months after primary completion.

Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's 28 months is close to that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 31, 2017
StartActual
Nov 1, 2017
Primary completionActual
Mar 21, 2020
CompletionActual
Mar 21, 2020
Results first posted
Sep 22, 2021
Last update
Sep 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03269435
Responsible party
Benjamin W. Friedman, MD (Professor, Montefiore Medical Center) — Principal investigator
First posted
Aug 31, 2017
Start date
Nov 1, 2017
Primary completion
Mar 21, 2020
Completion
Mar 21, 2020
Results posted
Sep 22, 2021
Last update
Sep 22, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion